All In Biotech

Drug Trial Radar · NCT07040137

Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration

Phase III Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

142

Planned (sponsor's estimate)

Start

Aug 15, 2025

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of KPS-0373 given once daily after breakfast in 142 patients with spinocerebellar degeneration . This study consists of the 4-week screening period, 24-week treatment period, and 4-week follow-up period.

Conditions

  • Spinocerebellar Degeneration

Interventions

  • KPS-0373Drug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in SARA total score at 24 weeks of treatment periodTime frame: Up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Tokyo and Other Japanese Cities, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.